Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
218.97
+6.58 (+3.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
November 15, 2022
From
BeiGene
Via
Business Wire
What 4 Analyst Ratings Have To Say About BeiGene
November 10, 2022
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter:
Via
Benzinga
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
November 10, 2022
From
BeiGene
Via
Business Wire
Is This Chinese Pharmaceutical Stock Worth the Risk?
November 03, 2022
BeiGene's shares are down this year, but it has two potential blockbusters.
Via
The Motley Fool
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
October 14, 2022
Via
Benzinga
Analyst Ratings for BeiGene
October 13, 2022
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter:
Via
Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
September 20, 2022
Via
Benzinga
Tesla, Amazon, Coupang, Rivian, Beigene: Musk's Share Sale, Antitrust Lawsuit, Earnings Grab Retail Investors' Eyeballs
November 09, 2022
Major Wall Street indices closed nearly 2% lower on Wednesday after the day was marred by uncertainties including the outcome of the mid-term elections and a sell-off in the cryptocurrency...
Via
Benzinga
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
November 04, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
November 03, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
November 02, 2022
From
BeiGene
Via
Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
October 26, 2022
From
BeiGene
Via
Business Wire
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
October 19, 2022
Via
Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
October 18, 2022
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its...
Via
Benzinga
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
October 15, 2022
Deals, financings, trials and approvals on the China biotech/pharma market.
Via
Talk Markets
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
October 14, 2022
From
BeiGene
Via
Business Wire
BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins
October 12, 2022
A smaller biotech tested its experimental leukemia drug against J&J's approved med.
Via
Investor's Business Daily
BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment
October 12, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
Upgrades
Via
Benzinga
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
October 12, 2022
From
BeiGene
Via
Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
September 19, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
September 19, 2022
From
BeiGene
Via
Business Wire
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
September 12, 2022
Via
Benzinga
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
September 10, 2022
From
BeiGene
Via
Business Wire
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
September 09, 2022
Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the...
Via
Benzinga
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022
From
BeiGene
Via
Business Wire
U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say
September 02, 2022
Key Takeaways: Despite a landmark U.S.-China information-sharing agreement, some predict dual listings in New York and Hong Kong will remain the preferred choice for Chinese...
Via
Benzinga
7 Chinese Stocks to Sell While You Still Can
September 02, 2022
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure
Via
InvestorPlace
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
August 30, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.